CJC-1295 with DAC Dosage Protocol Guide: Modified GRF Research (2026)

# CJC-1295 with DAC Dosage Protocol Guide: Modified GRF Research (2026)

> Research Use Only (RUO) Disclaimer: CJC-1295 with DAC is not approved by the FDA or any regulatory authority for human use. All information below is intended strictly for scientific research purposes. Not for human consumption, therapeutic use, or self-administration.

CJC-1295 with DAC vs. CJC-1295 without DAC: The Critical Distinction

When researching GHRH analogs, the distinction between CJC-1295 with DAC and CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF 1-29) is clinically significant and often misunderstood. The two compounds share the same core peptide sequence but differ fundamentally in their pharmacokinetic behavior due to a single modification: the Drug Affinity Complex (DAC) technology.

CJC-1295 without DAC (Mod GRF 1-29):

• •Half-life: ~30 minutes
• •Must be administered multiple times daily to sustain GH pulsatility
• •Produces acute, pronounced GH pulses — more closely mimics natural GHRH release

CJC-1295 with DAC:

• •Half-life: ~6–8 days
• •Once-weekly or twice-weekly dosing is sufficient
• •Produces sustained, elevated GH release — sometimes described as a "GH bleed" rather than a pulse
• •The DAC technology enables covalent binding to serum albumin, dramatically extending circulation time

For research purposes, this distinction shapes every aspect of the experimental design — from dosing frequency to the GH secretion pattern being studied.

Mechanism of Action: The DAC Technology Explained

CJC-1295 with DAC works by binding to growth hormone-releasing hormone receptors (GHRHR) in the anterior pituitary. The underlying peptide is a 29-amino acid analog of endogenous GHRH(1-44) stabilized against dipeptidyl peptidase IV (DPP-IV) degradation through strategic amino acid substitutions (Ala2 → D-Ala, Gln8 → Gln, Ala15 → Ala, Leu27 → Leu).

The DAC modification adds a maleimidoproprionic acid (MPA) group — a reactive thiol-binding moiety — to the C-terminus of the peptide. After injection, this reactive group forms a covalent bond with cysteine-34 on circulating serum albumin. Because albumin has a half-life of approximately 19 days, the bound CJC-1295 is shielded from renal clearance and proteolytic degradation, resulting in the extended 6–8 day half-life.

Effect on GH secretion patterns:

Unlike pulsatile GHRH stimulation (short-half-life analogs), CJC-1295 with DAC produces a sustained tonic elevation of GH. Research in rats and humans has demonstrated that a single injection of CJC-1295 with DAC results in elevated GH levels for 6–10 days. IGF-1, which is downstream of GH in the GH/IGF-1 axis, is elevated proportionally and sustains elevation throughout the dosing window.

Reconstitution Protocol

CJC-1295 with DAC is supplied as a lyophilized powder in research-grade vials, typically in 2 mg quantities.

Standard reconstitution:

1. Solvent: Bacteriostatic water (0.9% benzyl alcohol in sterile water) — standard for multi-dose vials

2. Target concentration: 2 mg/mL (add 1 mL BAC water to a 2 mg vial) or 1 mg/mL (add 2 mL)

3. Procedure:

- Allow vial to reach room temperature (15–20 minutes)

- Insert needle through the rubber stopper at a 45° angle

- Slowly inject BAC water down the side of the vial wall — never directly onto the lyophilized cake

- Gently swirl in circular motions for 30–60 seconds until fully dissolved

- Solution should appear clear and colorless; cloudiness or particulate matter indicates degradation or improper reconstitution

4. Storage post-reconstitution: Refrigerate at 2–8°C; stable for 4–6 weeks. Avoid repeated freeze-thaw cycles.

5. Lyophilized storage: –20°C; stable 24+ months in dry conditions

Dosage Protocols in Research Models

Standard Research Dosing

Based on published literature and research protocols:

Key pharmacokinetic considerations:

• •Peak GH elevation occurs at approximately 2–6 hours post-injection
• •GH remains above baseline for 6–10 days post-injection
• •IGF-1 elevation lags GH by 12–24 hours and sustains elevation for the full dosing window
• •Steady-state GH/IGF-1 elevation is typically reached after 2–4 weeks of consistent weekly dosing

Cycling Framework

Research protocols using CJC-1295 with DAC typically run for defined periods to avoid desensitization of pituitary GHRHR:

• •Short research cycle: 8–12 weeks on, 4 weeks off
• •Longer research cycle: 16–20 weeks on, 6–8 weeks off
• •Continuous monitoring protocol: Run with GH/IGF-1 measurements at weeks 2, 4, 8, 12 to assess saturation and pituitary response

Combination with GHRPs and Ipamorelin

CJC-1295 with DAC is frequently studied in combination with growth hormone releasing peptides (GHRPs) — specifically Ipamorelin, GHRP-2, or GHRP-6. The rationale is synergistic:

• •CJC-1295 with DAC provides tonic GHRH signaling, priming the pituitary
• •GHRPs (ghrelin mimetics) provide acute pulsatile stimulation of GH release
• •Together, they produce GH pulse amplitudes greater than either agent alone

Combination research dosing:

• •CJC-1295 with DAC: 1–2 mg once weekly (subcutaneous)
• •Ipamorelin (preferred for clean GH profile without cortisol/prolactin elevation): 100–200 mcg 2–3× daily (subcutaneous)

This combination is among the most frequently studied in GH axis research models.

Monitoring Parameters

For responsible research protocols, the following biomarkers should be tracked:

• •IGF-1 (Insulin-like Growth Factor-1): Primary surrogate for sustained GH activity; drawn at baseline and at regular intervals
• •GH (Growth Hormone): For acute response assessment; drawn 2–6 hours post-injection
• •Glucose: GH can induce transient insulin resistance; fasting glucose monitoring is standard
• •Cortisol: Unlike some GHRPs, CJC-1295 with DAC does not independently stimulate cortisol, but combination protocols should include cortisol assessment

Comparative Research: CJC-1295 with DAC vs. Sermorelin

Sermorelin (GHRH 1-29) is the oldest and most studied GHRH analog. Compared to CJC-1295 with DAC:

Sermorelin is FDA-approved for pediatric growth hormone deficiency, while CJC-1295 with DAC remains a research compound. Researchers studying long-term GH/IGF-1 axis dynamics often prefer CJC-1295 with DAC for practical reasons — weekly dosing simplifies experimental design and reduces variability from missed doses.

Key Research Findings

The foundational clinical research on CJC-1295 with DAC was published by Jetté et al. (2005) in the Journal of Clinical Endocrinology & Metabolism. Key findings from this dose-ranging study in healthy adults:

• •Single doses of 30–60 mcg/kg produced dose-dependent GH area-under-the-curve increases of 2–10 fold over 6 days
• •IGF-1 increased 1.5–3 fold and remained elevated for 9–11 days
• •No serious adverse events were reported at research doses
• •The albumin-binding mechanism was confirmed via the DAC technology's behavior in vivo

Safety Considerations for Research Contexts

All research protocols involving CJC-1295 with DAC should account for:

• •Potential for water retention: GH elevation can cause transient sodium and water retention — relevant in metabolic research models
• •Glucose homeostasis effects: Sustained GH elevation can reduce peripheral insulin sensitivity; researchers studying metabolic parameters should monitor fasting glucose
• •Pituitary desensitization: Prolonged continuous GHRHR stimulation may reduce receptor sensitivity; appropriate washout periods between research cycles are standard practice
• •Interaction with insulin: GH and insulin have counter-regulatory relationships; combination experiments require careful protocol design

Conclusion

CJC-1295 with DAC represents one of the most practically useful tools in GHRH analog research due to its extended half-life and once-weekly dosing convenience. The DAC technology — covalent albumin binding — fundamentally transforms the pharmacokinetics of a short-lived GHRH analog into a depot-like formulation with sustained GH/IGF-1 axis stimulation. Researchers studying GH replacement paradigms, GH/IGF-1 axis dynamics, or combination secretagogue protocols consistently choose CJC-1295 with DAC for its practical advantages over short-acting analogs.

For research purposes only. Not for human use. Always obtain appropriate institutional approvals before conducting peptide research.

---

This article is for educational and research purposes only. Peptides.SO does not endorse or encourage the use of research compounds for human consumption. Consult a licensed healthcare professional for any medical concerns.